Business
ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update
MENLO PARK, Calif., September 29, 2025--ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced the close of over $29 million in additional financing. The company also reported expanded support from the Cystic Fibrosis Foundation (CF Foundation) and a new research collaboration with Praxis Precision Medicines, Inc. (NASDAQ: PRAX).
About this update from Praxis Precision Medicines, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2000,"height":673,"url":"https://media.zenfs.com/en/business-wire.com/986ef2081ebf54b690d80f9a34b0c75e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WRXOFUrl0YzhV6EHNzW49g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyMztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/986ef2081ebf54b690d80f9a34b0c75e","width":960,"height":323},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/gqtO_dClroQJEa_8Dq946Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MDg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/986ef2081ebf54b690d80f9a34b0c75e","width":1200,"height":404}},"lazy":false},{"type":"text","content":"– Cystic Fibrosis Foundation provides $3 million in new funding to accelerate development of inhaled mRNA therapy for cystic fibrosis –","length":135,"tagName":"p","attribs":{}},{"type":"text","content":"– Research collaboration with Praxis Precision Medicines to develop LNP formulations for ASO delivery –","length":103,"tagName":"p","attribs":{}},{"type":"text","content":"MENLO PARK, Calif., September 29, 2025--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced the close of over $29 million in additional financing. The company also reported expanded support from the Cystic Fibrosis Foundation (CF Foundation) and a new research collaboration with Praxis Precision Medicines, Inc. (NASDAQ: PRAX).","length":469,"tagName":"p"},{"type":"text","content":""With continued support from organizations like the CF Foundation and our collaboration with Praxis, we are building on our momentum to deliver on the promise of genetic medicines for people living with genetic diseases who currently have limited or no effective treatments," said Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer of ReCode Therapeutics.","length":376,"tagName":"p"},{"type":"text","content":"Key Updates","length":11,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Over $29 Million Raised in New Financing: ReCode has raised more than $29 million to advance its pipeline of genetic medicines, including investigational therapies for cystic fibrosis (CF). The f...